Sponsored • POCT

Pluslife Biotech – Mini Dock POC Molecular System

The Pluslife Mini Dock System is a Next-Generation POC molecular diagnostic tool that can be used in different application scenarios, which aims to help the decentralization of MDx in diagnosing facilities.

Photo

Complete POC Molecular Testing Solution (Isothermal Amplification Chip Method) 

  • Analyzers, Mini Dock and 8-Channel 
  • 16 Tests, 
    • Pandemic Control - SARS-CoV-2, Monkeypox
    • Respiratory Health - SARS-CoV-2/Flu A/Flu B, RSV/Flu A/Flu B, Strep A, M.P
    • Sexual Health - STD (NG/UU), STD (CT/NG/UU), HPV 16/18/45, HPV 6/11, Strep B (GBS)
    • Animal Health - Feline (FHV-1/C.felis/M.felis), Feline (FHV-1/C.felis/M.felis/Bb), Canine (CDV/CPIV/CAV-2/Bb), ASFV

Features:

  • Performance: 98.91% Sensitivity, 100% Specificity, LoD 400 Copies/mL
  • Compact, 
    • Palmed-sized Mink Dock (~210g), weight less than iPhone 14 (~240g)
    • 8-Channel Analyzer, benchtop and stackable design
  • Accurate, equivalent to qPCR tests
  • Fast, 3-step process (sampling → mixing → run test), results in 15~30 mins
  • Powerful, one test up to 6 pathogens
  • Competitive Cost, reusable analyzers and room temperature storage test cards

Find us at MEDICA 2022 Booth No.1 1H39-7 or visit https://www.pluslife.com/ for more detail. 

Website: https://www.pluslife.com/ 

03.11.2022

Read all latest stories

Related articles

Photo

Sponsored • Diagnostics Alliance against SARS-CoV-2

The Global Alliance for Diagnostics Sets Next-Generation POC Molecular Testing Collaboration

The coronavirus pandemic is a huge challenge for global public health and welfare. Decentralized, affordable POC MDx platforms would allow more effective control of SARS-CoV-2 and other infections.

Photo

News • "COMPASS" method

Using nanoparticles for more sensitive rapid tests

A newly developed rapid test needs only a few seconds to reliably detect pathogens such as SARS-CoV-2. It is based on specially designed magnetic nanoparticles.

Photo

News • Deep mutational scanning for SARS-CoV-2

Preparing rapid tests for future coronavirus variants

How can rapid antigen tests be adjusted to reliably detect future variants of SARS-CoV-2? A research team funded by the National Institutes of Health is currently working on finding an answer.

Related products

Pluslife Biotech – Mini Dock POC Molecular System

POCT

Pluslife Biotech – Mini Dock POC Molecular System

Guangzhou Pluslife Biotech Co., Ltd.
Pluslife Biotech – Mini Dock POC Molecular System

POCT

Pluslife Biotech – Mini Dock POC Molecular System

Guangzhou Pluslife Biotech Co., Ltd.
Sense Biodetection, Ltd. - Veros Covid-19

Other

Sense Biodetection, Ltd. - Veros Covid-19

Sense Biodetection, Ltd.
Nova Biomedical – StatStrip Glucose/Ketone*

Blood Glucose

Nova Biomedical – StatStrip Glucose/Ketone*

Nova Biomedical Corporation
Subscribe to Newsletter